Webinar- Utilizing the exoscope in neurosurgical oncology

Utilizing the exoscope in neurosurgical oncology

Explained by Dr. Nader Sanai

see Video here

The following time-stamps will guide you to certain key points & examples during this webinar:

At 1:30: “Moving from a pure optical platform to a digital platform is something that we are going to see increasingly in our operating rooms”

At 3:10: “As a tumor surgeon, we have multiple information chains, we have the structural MRI, functional MRI, tractography, MR spectroscopy, MAG imaging, fluorescence-guided surgery, intraoperative navigation and all of these things have to be integrated in our brains and extrapolated through our actions with the tumor. I think what this platform (ZEISS KINEVO 900) is enabling us to do, is give us the ability to integrate a lot of this in real-time so that we do not have to do this ourselves and we do not have to be swiveling our heads to look at this scan or that scan as we are operating.”

At 6:01: “Now, the PointLock concept is really one where you want to specifically focus on a particular target in three-dimensional space. But you want to be able to pivot around it without having to find it again. We all do that in the OR and while it may take only few seconds, those are precious seconds where you lose your chain of thoughts. [..] Achieving this at a functional level… and by that I mean the ability where the robot does it for you and you do not have to adjust at all in terms of fine tuning the focus or fine tuning the special referencing [..] I have used it in the OR, really without any training on it and it is something very intuitive.”

At 7:17: “Many of us use MRI spectroscopy (for example) to identify hotspots where we will perform biopsy. For example, in a low grade tumor we want to decrease the chance of missing a focus of transformation. By bookmarking those sites on the microscope, we can make sure that we can go directly to that spot without worrying about aligning the navigation and all of the other anatomical information around it.”

At 9:06: “In brain tumor operations there are many dimensions of the tumor that we need to work along and we often operate – move the microscope – operate. This platform enables you to continuously operate as you are moving. And, if you are using it as an exoscope function (particularly), you, yourself don’t have to move at all. Effectively, the microscope moves and you stay still. [..] it is an important distinction when you are doing a multi-hour operation and you are able to stay in a position of comfort and stability [..] instead of moving around your torso to accommodate the dimension.”

At 11:03: “The next generation of microscope will be something that is not so much part of you but is working in parallel with you. [..] For example, in a far-lateral type approach for lower cranial schwannoma, there are issues in positioning and the angle of view. But here we can operate in a relatively neutral position using 3D 4K visualization.“

At 13:13: Case explanation for Retrosigmoid Crainiotomy for Petrous Face Meningioma using the combination of exoscopic visualization and robotics.

At 13:54: “This is at the point where one can transition to the exoscope. Because the angles of approach that you want as you are trying to pull this tumor away from the brain tumor margins, really can be quite extreme. You can see in the inset where the angle of the microscope head is relative to my head. If I had to stretch to get to that angle I’m going to be relatively uncomfortable and less stable ergonomically with my hands and torso.”

At 15:12: “I would also add that the learning curve for this is not very steep. It is a relatively simple device to adopt into your workflow because many of us have already gotten used to using the foot pedal for basic robotic movements of the microscope head. What this does is: add these additional dimensions of moving in an angle and pivoting around a point. So, it is really like a real-time surveillance image happening as you operate.

At 16.31: “The digital integration of real-time functional imaging, real-time tractography, real-time stimulation mapping data into the cortex will basically make it seamless.”

Eso Masterclass In Neuro-Oncology: Multidisciplinary Management Of Adult Brain Tumour

September 20 — September 22

Milan, Italy

Programme

The European School of Oncology was founded by Umberto Veronesi and Laudomia Del Drago in 1982, with the aim of contributing to the reduction of deaths from cancer due to late diagnosis and/or inadequate treatment. By improving the skills of all health professionals dealing with cancer patients, ESO helps shorten the time needed to transfer knowledge from research centres to daily practice, combining advanced technology with humanism in care.

ESO’s mission is reflected in its motto “Learning to Care”, which emphasises the importance of the learning process, and the goal of caring for the patient in a holistic sense, in contrast to focusing purely on treating the disease.

Due to its financial independence, ESO has the rare privilege of being able to set its own priorities. It therefore pays particular attention to developing the transfer of knowledge in areas that are least supported by industry, such as surgery and in rare pathologies (including childhood tumours), and in countries and regions with limited economic resources.

Fluorescence-Guided Neurosurgery: Neuro-oncology and Cerebrovascular Applications

The definitive textbook on state-of-the-art fluorescence-guided neurosurgery

Advances in fluorescence-guided surgery (FGS) have resulted in a paradigm shift in neurosurgical approaches to neuro-oncological and cerebrovascular pathologies. Edited by two of the foremost authorities on the topic, Fluorescence-Guided Neurosurgery: Neuro-oncology and Cerebrovascular Applications encompasses the depth and breadth of this groundbreaking, still nascent technology. The book reflects significant contributions made by world renowned neurosurgeons Constantinos Hadjipanayis, Walter Stummer, and esteemed contributors on the growing uses of 5-aminolevulinic acid (5-ALA) and other FGS agents.

The European Medicine Agency approved 5-ALA in 2007, heralding the birth of FGS globally. In 2017, the U.S. Food and Drug Administration approved 5-ALA (Gleolan) as an imaging agent to facilitate realtime detection and visualization of malignant tissue during glioma surgery. In the two decades since Dr. Stummer’s initial description of 5-ALA FGS in a human patient, major strides have been made in its practical applications, leading to improved resection outcomes. As FGS is increasingly incorporated into neurosurgical practice, it holds promise for future innovations. Generously-illustrated and enhanced with online videos, this textbook is the definitive resource on the subject.

Key Features

  • The improved efficacy of 5-ALA for resecting high- and low-grade gliomas, recurrences, meningiomas, brain metastases, spinal cord tumors, pediatric brain tumors, and other adult tumors
  • The future of fluorescence, including potentially powerful new fluorophores molecularly targeted specifically to tumors
  • The use of the fluorescent agent indocyanine green (ICG) for brain tumors, cerebral aneurysms, AVMs, and cerebral vascularization
  • Special topics such as fluorescein, illuminating tumor paint, confocal microscopy, Raman spectroscopy, and integrating FGS with intraoperative imaging and brain mapping

This single accessible reference presents the current state-of-the-art on this emerging, exciting surgical technology. As such, it is a must-have for neurosurgical residents, fellows, and practicing neurosurgeons.

 

 

Neuro-Oncology January 2017

1: Antonios JP, Soto H, Everson RG, Moughon D, Orpilla JR, Shin NP, Sedighim S,
Treger J, Odesa S, Tucker A, Yong WH, Li G, Cloughesy TF, Liau LM, Prins RM.
Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune
resistance via a PD-1/PD-L1 mechanism in glioblastoma. Neuro Oncol. 2017 Jan 23.
pii: now287. doi: 10.1093/neuonc/now287. [Epub ahead of print] PubMed PMID:
28115578.
2: Ramkissoon SH, Bandopadhayay P, Hwang J, Ramkissoon LA, Greenwald NF,
Schumacher SE, O’Rourke R, Pinches N, Ho P, Malkin H, Sinai C, Filbin M, Plant A,
Bi WL, Chang MS, Yang E, Wright KD, Manley PE, Ducar M, Alexandrescu S, Lidov H,
Delalle I, Goumnerova LC, Church AJ, Janeway KA, Harris MH, MacConaill LE,
Folkerth RD, Lindeman NI, Stiles CD, Kieran MW, Ligon AH, Santagata S, Dubuc AM,
Chi SN, Beroukhim R, Ligon KL. Clinical targeted exome-based sequencing in
combination with genome-wide copy number profiling: precision medicine analysis
of 203 pediatric brain tumors. Neuro Oncol. 2017 Jan 19. pii: now294. doi:
10.1093/neuonc/now294. [Epub ahead of print] PubMed PMID: 28104717.
3: Berghoff AS, Wolpert F, Holland-Letz T, Koller R, Widhalm G, Gatterbauer B,
Dieckmann K, Birner P, Bartsch R, Zielinski CC, Weller M, Preusser M. Combining
standard clinical blood values for improving survival prediction in patients with
newly diagnosed brain metastases-development and validation of the LabBM score.
Neuro Oncol. 2017 Jan 17. pii: now290. doi: 10.1093/neuonc/now290. [Epub ahead of
print] PubMed PMID: 28096493.
4: Altinoz MA, Guloksuz S, Elmaci I. Rabies virus vaccine as an immune adjuvant
against cancers and glioblastoma: new studies may resurrect a neglected
potential. Clin Transl Oncol. 2017 Jan 16. doi: 10.1007/s12094-017-1613-6. [Epub
ahead of print] Review. PubMed PMID: 28093702.
5: Sun Y, Alberta JA, Pilarz C, Calligaris D, Chadwick EJ, Ramkissoon SH,
Ramkissoon LA, Garcia VM, Mazzola E, Goumnerova L, Kane M, Yao Z, Kieran MW,
Ligon KL, Hahn WC, Garraway LA, Rosen N, Gray NS, Agar NY, Buhrlage SJ, Segal RA,
Stiles CD. A brain-penetrant RAF dimer antagonist for the noncanonical BRAF
oncoprotein of pediatric low-grade astrocytomas. Neuro Oncol. 2017 Jan 12. pii:
now261. doi: 10.1093/neuonc/now261. [Epub ahead of print] PubMed PMID: 28082416.
6: Boetto J, Bielle F, Sanson M, Peyre M, Kalamarides M. SMO mutation status
defines a distinct and frequent molecular subgroup in olfactory groove
meningiomas. Neuro Oncol. 2017 Jan 12. pii: now276. doi: 10.1093/neuonc/now276.
[Epub ahead of print] PubMed PMID: 28082415.
7: Teng J, Carla da Hora C, Kantar RS, Nakano I, Wakimoto H, Batchelor TT,
Chiocca EA, Badr CE, Tannous BA. Dissecting inherent intratumor heterogeneity in
patient-derived glioblastoma culture models. Neuro Oncol. 2017 Jan 6. pii:
now253. doi: 10.1093/neuonc/now253. [Epub ahead of print] PubMed PMID: 28062830.
8: Zhu C, Mustafa D, Zheng PP, van der Weiden M, Sacchetti A, Brandt M, Chrifi I,
Tempel D, Leenen PJ, Duncker DJ, Cheng C, Kros JM. Activation of CECR1 in M2-like
TAMs promotes paracrine stimulation-mediated glial tumor progression. Neuro
Oncol. 2017 Jan 3. pii: now251. doi: 10.1093/neuonc/now251. [Epub ahead of print]
PubMed PMID: 28053137.
9: Darlix A, Gozé C, Rigau V, Bauchet L, Taillandier L, Duffau H. The
etiopathogenesis of diffuse low-grade gliomas. Crit Rev Oncol Hematol. 2017
Jan;109:51-62. doi: 10.1016/j.critrevonc.2016.11.014. Review. PubMed PMID:
28010898.
10: Wei JW, Huang K, Yang C, Kang CS. Non-coding RNAs as regulators in
epigenetics (Review). Oncol Rep. 2017 Jan;37(1):3-9. doi: 10.3892/or.2016.5236.
PubMed PMID: 27841002.
11: Avila EK, Chamberlain M, Schiff D, Reijneveld JC, Armstrong TS, Ruda R, Wen
PY, Weller M, Koekkoek JA, Mittal S, Arakawa Y, Choucair A, Gonzalez-Martinez J,
MacDonald DR, Nishikawa R, Shah A, Vecht CJ, Warren P, van den Bent MJ, DeAngelis
LM. Seizure control as a new metric in assessing efficacy of tumor treatment in
low-grade glioma trials. Neuro Oncol. 2017 Jan;19(1):12-21. doi:
10.1093/neuonc/now190. Review. PubMed PMID: 27651472; PubMed Central PMCID:
PMC5193028.
12: Guidi M, Giunti L, Lucchesi M, Scoccianti S, Giglio S, Favre C, Oliveri G,
Sardi I. Brain tumors in Li-Fraumeni syndrome: a commentary and a case of a
gliosarcoma patient. Future Oncol. 2017 Jan;13(1):9-12. PubMed PMID: 27523101.
13: Hu LS, Ning S, Eschbacher JM, Baxter LC, Gaw N, Ranjbar S, Plasencia J, Dueck
AC, Peng S, Smith KA, Nakaji P, Karis JP, Quarles CC, Wu T, Loftus JC, Jenkins
RB, Sicotte H, Kollmeyer TM, O’Neill BP, Elmquist W, Hoxworth JM, Frakes D,
Sarkaria J, Swanson KR, Tran NL, Li J, Mitchell JR. Radiogenomics to characterize
regional genetic heterogeneity in glioblastoma. Neuro Oncol. 2017
Jan;19(1):128-137. doi: 10.1093/neuonc/now135. PubMed PMID: 27502248; PubMed
Central PMCID: PMC5193022.
14: Li S, Zeng A, Hu Q, Yan W, Liu Y, You Y. miR-423-5p contributes to a
malignant phenotype and temozolomide chemoresistance in glioblastomas. Neuro
Oncol. 2017 Jan;19(1):55-65. doi: 10.1093/neuonc/now129. PubMed PMID: 27471108;
PubMed Central PMCID: PMC5193021.
15: Goffart N, Lombard A, Lallemand F, Kroonen J, Nassen J, Di Valentin E,
Berendsen S, Dedobbeleer M, Willems E, Robe P, Bours V, Martin D, Martinive P,
Maquet P, Rogister B. CXCL12 mediates glioblastoma resistance to radiotherapy in
the subventricular zone. Neuro Oncol. 2017 Jan;19(1):66-77. doi:
10.1093/neuonc/now136. PubMed PMID: 27370398; PubMed Central PMCID: PMC5193023.
16: Zhang B, Chang K, Ramkissoon S, Tanguturi S, Bi WL, Reardon DA, Ligon KL,
Alexander BM, Wen PY, Huang RY. Multimodal MRI features predict isocitrate
dehydrogenase genotype in high-grade gliomas. Neuro Oncol. 2017
Jan;19(1):109-117. doi: 10.1093/neuonc/now121. PubMed PMID: 27353503; PubMed
Central PMCID: PMC5193019.

Book: Handbook of Neuro-Oncology Neuroimaging, Second Edition

Handbook of Neuro-Oncology Neuroimaging, Second Edition

Handbook of Neuro-Oncology Neuroimaging, Second Edition
Price: $210.00
ADD TO SHOPPING CART
Remarkable progress in neuro-oncology due to increased utilization of advanced imaging in clinical practice continues to accelerate in recent years. Refinements in magnetic resonance imaging (MRI) and computed tomography (CT) technology, and the addition of newer anatomical, functional, and metabolic imaging methods, such as MRS, fMRI, diffusion MRI, and DTI MRI have allowed brain tumor patients to be diagnosed much earlier and to be followed more carefully during treatment. With treatment approaches and the field of neuro-oncology neuroimaging changing rapidly, this second edition of the Handbook of Neuro-Oncology Neuroimaging is so relevant to those in the field, providing a single-source, comprehensive, reference handbook of the most up-to-date clinical and technical information regarding the application of neuro-Imaging techniques to brain tumor and neuro-oncology patients. This new volume will have updates on all of the material from the first edition, and in addition will feature several new important chapters covering diverse topics such as advanced imaging techniques in radiation therapy, therapeutic treatment fields, response assessment in clinical trials, surgical planning of neoplastic disease of the spine, and more. It will also serve as a resource of background information to neuroimaging researchers and basic scientists with an interest in brain tumors and neuro-oncology.

  • Provides a background to translational research and the use of brain imaging for brain tumors
  • Contains critical discussions on the potential and limitations of neuroimaging as a translational tool for the diagnosis and treatment of brain tumor and neuro-oncology patients
  • Presents an up-to-date reference on advanced imaging technologies, including computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET), as well as the recent refinements in these techniques

Product Details

  • Published on: 2016-04-26
  • Original language: English
  • Number of items: 1
  • Dimensions: 10.90″ h x 1.80″ w x 8.60″ l, 6.68 pounds
  • Binding: Hardcover
  • 864 pages